.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A subsequent randomized trial refined the bedaquiline–pretomanid–linezolid approach by examining shorter and lower-intensity linezolid strategies in drug-resistant tuberculosis. The study included multiple BPaL-based treatment groups and showed that favorable outcomes remained high even when the linezolid component was reduced, while toxicity decreased with less linezolid exposure. Neuropathy and hematologic adverse effects were important limitations of the original regimen, so the findings have practical significance for treatment tolerability. For clinicians, the paper demonstrates how regimen optimization can be clinically as important as discovering a new drug. The aim is not simply to maximize antimicrobial intensity, but to maintain efficacy while minimizing preventable toxicity and treatment interruption. This is especially relevant in settings where follow-up capacity varies and patients may face long distances or financial barriers to repeated care. The findings strengthen a patient-centered approach to drug-resistant TB and fit the conference discussion of adherence as more than a behavioral issue: regimen length, adverse effects, monitoring, and access all shape whether patients can successfully complete treatment.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A subsequent randomized trial refined the bedaquiline–pretomanid–linezolid approach by examining shorter and lower-intensity linezolid strategies in drug-resistant tuberculosis. The study included multiple BPaL-based treatment groups and showed that favorable outcomes remained high even when the linezolid component was reduced, while toxicity decreased with less linezolid exposure. Neuropathy and hematologic adverse effects were important limitations of the original regimen, so the findings have practical significance for treatment tolerability. For clinicians, the paper demonstrates how regimen optimization can be clinically as important as discovering a new drug. The aim is not simply to maximize antimicrobial intensity, but to maintain efficacy while minimizing preventable toxicity and treatment interruption. This is especially relevant in settings where follow-up capacity varies and patients may face long distances or financial barriers to repeated care. The findings strengthen a patient-centered approach to drug-resistant TB and fit the conference discussion of adherence as more than a behavioral issue: regimen length, adverse effects, monitoring, and access all shape whether patients can successfully complete treatment.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
6 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
Last week
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
Last week
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
Last week
